S&P 500   3,327.56 (-0.06%)
DOW   29,310.20 (-0.13%)
QQQ   223.62 (+0.11%)
AAPL   317.99 (-0.23%)
FB   221.28 (-0.39%)
MSFT   167.59 (+0.29%)
GOOGL   1,480.73 (+0.08%)
AMZN   1,870.38 (+0.30%)
CGC   24.46 (-1.73%)
NVDA   248.73 (-0.22%)
BABA   221.38 (-2.66%)
MU   58.52 (+1.49%)
GE   11.71 (-0.85%)
TSLA   540.62 (+5.90%)
AMD   51.21 (+0.53%)
T   38.44 (+0.13%)
F   9.17 (+0.11%)
NFLX   336.70 (-0.87%)
BAC   34.47 (-0.69%)
GILD   62.82 (-0.25%)
DIS   143.74 (-0.41%)
S&P 500   3,327.56 (-0.06%)
DOW   29,310.20 (-0.13%)
QQQ   223.62 (+0.11%)
AAPL   317.99 (-0.23%)
FB   221.28 (-0.39%)
MSFT   167.59 (+0.29%)
GOOGL   1,480.73 (+0.08%)
AMZN   1,870.38 (+0.30%)
CGC   24.46 (-1.73%)
NVDA   248.73 (-0.22%)
BABA   221.38 (-2.66%)
MU   58.52 (+1.49%)
GE   11.71 (-0.85%)
TSLA   540.62 (+5.90%)
AMD   51.21 (+0.53%)
T   38.44 (+0.13%)
F   9.17 (+0.11%)
NFLX   336.70 (-0.87%)
BAC   34.47 (-0.69%)
GILD   62.82 (-0.25%)
DIS   143.74 (-0.41%)
S&P 500   3,327.56 (-0.06%)
DOW   29,310.20 (-0.13%)
QQQ   223.62 (+0.11%)
AAPL   317.99 (-0.23%)
FB   221.28 (-0.39%)
MSFT   167.59 (+0.29%)
GOOGL   1,480.73 (+0.08%)
AMZN   1,870.38 (+0.30%)
CGC   24.46 (-1.73%)
NVDA   248.73 (-0.22%)
BABA   221.38 (-2.66%)
MU   58.52 (+1.49%)
GE   11.71 (-0.85%)
TSLA   540.62 (+5.90%)
AMD   51.21 (+0.53%)
T   38.44 (+0.13%)
F   9.17 (+0.11%)
NFLX   336.70 (-0.87%)
BAC   34.47 (-0.69%)
GILD   62.82 (-0.25%)
DIS   143.74 (-0.41%)
S&P 500   3,327.56 (-0.06%)
DOW   29,310.20 (-0.13%)
QQQ   223.62 (+0.11%)
AAPL   317.99 (-0.23%)
FB   221.28 (-0.39%)
MSFT   167.59 (+0.29%)
GOOGL   1,480.73 (+0.08%)
AMZN   1,870.38 (+0.30%)
CGC   24.46 (-1.73%)
NVDA   248.73 (-0.22%)
BABA   221.38 (-2.66%)
MU   58.52 (+1.49%)
GE   11.71 (-0.85%)
TSLA   540.62 (+5.90%)
AMD   51.21 (+0.53%)
T   38.44 (+0.13%)
F   9.17 (+0.11%)
NFLX   336.70 (-0.87%)
BAC   34.47 (-0.69%)
GILD   62.82 (-0.25%)
DIS   143.74 (-0.41%)
Log in
(Ad)
Its partners include AT&T, Verizon, Sprint and T-Mobile.

It owns more than 200 patents.

And analysts say it has "home-run potential."

Yet this 5G superstock trades for only $5 a share.

NASDAQ:XLRN - Acceleron Pharma Stock Price, Forecast & News

$55.74
-0.40 (-0.71 %)
(As of 01/21/2020 12:24 PM ET)
Today's Range
$55.45
Now: $55.74
$56.56
50-Day Range
$48.68
MA: $52.05
$56.24
52-Week Range
$37.01
Now: $55.74
$56.90
Volume6,050 shs
Average Volume358,564 shs
Market Capitalization$2.96 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.25
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XLRN
CUSIPN/A
Phone617-649-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.99 million
Book Value$6.32 per share

Profitability

Net Income$-118,870,000.00
Net Margins-353.57%

Miscellaneous

Employees173
Market Cap$2.96 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


2020 could be a monster year for cannabis stocks, especially with cannabis on many November ballots, and presidential candidates pushing for approval. In our latest special report, we detail five must-own cannabis stocks that could double, even triple your investment over the next year.

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc (NASDAQ:XLRN) posted its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.83) by $0.03. The biopharmaceutical company earned $4.20 million during the quarter, compared to analysts' expectations of $4.44 million. Acceleron Pharma had a negative net margin of 353.57% and a negative return on equity of 30.79%. The firm's revenue for the quarter was up 27.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.63) earnings per share. View Acceleron Pharma's Earnings History.

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Acceleron Pharma.

What price target have analysts set for XLRN?

12 brokers have issued 1 year price targets for Acceleron Pharma's shares. Their forecasts range from $45.00 to $88.00. On average, they anticipate Acceleron Pharma's share price to reach $60.82 in the next year. This suggests a possible upside of 9.2% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.

What is the consensus analysts' recommendation for Acceleron Pharma?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.

What are Wall Street analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:
  • 1. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (1/16/2020)
  • 2. HC Wainwright analysts commented, "We are lowering our price target to $68 from $69 due to the discontinuation of ACE-083 for FSHD. Our $68 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline, and estimated year-end cash." (9/17/2019)

Has Acceleron Pharma been receiving favorable news coverage?

Headlines about XLRN stock have been trending very positive this week, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Acceleron Pharma earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Acceleron Pharma.

Are investors shorting Acceleron Pharma?

Acceleron Pharma saw a decrease in short interest in the month of December. As of December 13th, there was short interest totalling 4,230,000 shares, a decrease of 6.8% from the November 28th total of 4,540,000 shares. Based on an average daily volume of 359,500 shares, the days-to-cover ratio is currently 11.8 days. Currently, 9.4% of the company's shares are short sold. View Acceleron Pharma's Current Options Chain.

Who are some of Acceleron Pharma's key competitors?

What other stocks do shareholders of Acceleron Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Cisco Systems (CSCO), Gilead Sciences (GILD), Incyte (INCY), LogicBio Therapeutics (LOGC), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Exelixis (EXEL), Intel (INTC) and Bausch Health Companies (BHC).

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:
  • Mr. Habib J. Dable, CEO, Pres & Director (Age 50)
  • Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 76)
  • Mr. Kevin F. McLaughlin, Sr. VP, CFO & Treasurer (Age 63)
  • Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 59)
  • Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 48)

Who are Acceleron Pharma's major shareholders?

Acceleron Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.19%), Neville Rodie & Shaw Inc. (0.04%), Zeke Capital Advisors LLC (0.02%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops and Sujay Kango. View Institutional Ownership Trends for Acceleron Pharma.

Which institutional investors are selling Acceleron Pharma stock?

XLRN stock was sold by a variety of institutional investors in the last quarter, including Neville Rodie & Shaw Inc., Zeke Capital Advisors LLC and Nisa Investment Advisors LLC. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango. View Insider Buying and Selling for Acceleron Pharma.

Which institutional investors are buying Acceleron Pharma stock?

XLRN stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $55.67.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $2.95 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.View Additional Information About Acceleron Pharma.

What is Acceleron Pharma's official website?

The official website for Acceleron Pharma is http://www.acceleronpharma.com/.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]


MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  488 (Vote Outperform)
Underperform Votes:  352 (Vote Underperform)
Total Votes:  840
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel